Saltar al contenido
Merck
  • High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.

High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.

Leukemia research (2013-01-30)
Mona Hassanein, Eshetu G Atenafu, Andre C Schuh, Karen W L Yee, Mark D Minden, Aaron D Schimmer, Vikas Gupta, Joseph M Brandwein
RESUMEN

We evaluated outcomes in two consecutive groups of AML patients age>60 years in CR after 7+3 induction therapy. Group 1 received consolidation with cytarabine 1.5g/m(2) q12h×6+daunorubicin for two cycles, while group 2 received consolidation with 7+3 followed by mitoxantrone+etoposide. For patients with intermediate-risk cytogenetics, group 1 had a significantly superior DFS (p=0.046), and a trend toward better OS (p=0.087). The treatment group remained a significant predictor of DFS on multivariate analysis. The results indicate that a high-dose cytarabine-containing consolidation regimen produces superior outcomes in AML patients age>60 years with intermediate-risk cytogenetics.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Mitoxantrone dihydrochloride, ≥97% (HPLC)
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Sigma-Aldrich
Daunorubicin hydrochloride, ≥90% (HPLC)
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Sigma-Aldrich
Daunorubicin hydrochloride, meets USP testing specifications
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Daunorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
En este momento no podemos mostrarle ni los precios ni la disponibilidad